Abstract 80P
Background
Pathological examination is essential to determine the cancer stage in colorectal cancer (CRC) patients, and histological examination of lymph nodes plays a pivotal role in the staging process. We previously reported a new fat-dissociation method (FM) to detect lymph nodes from surgically resected mesentery. It can reduce a fat volume of the mesentery and visualize a structure of vessels and lymph nodes. In this study we examined the effectiveness of the FM compared with a conventional palpation method in CRC.
Methods
A single center, open-label, randomized controlled study was performed at Osaka International Cancer Institute (OICC) in Japan from January, 2014, to December, 2014. Randomization was done via a computer-generated permuted-block sequence, and was stratified by surgical procedures and the dissection area of lymph nodes (ie, D2 or D3). Primary endpoint was set at the time to search lymph nodes. Secondary endpoint was set at the number of lymph nodes and 5-year overall survival (OS).
Results
130 patients were enrolled to this study and randomly assigned in a one to one ratio: 65 to the FM group and 65 to the conventional palpation (CP) group. Searching time were 15.9 (±0.6) minutes in the FM group and 45.1 (±1.5) minutes in the CP group (P < 0.001). In CP group there was correlation between BMI and searching time (P = 0.047). Numbers of lymph nodes were 21.5 (±1.9) in the FM group and 19.6 (±1.4) in the CP group (P = 0.546). In right-side CRC, the number of lymph nodes was more in the FM group (32.6±4.5) than the CP group (21.7±2.6) (P = 0.030). 5-year OS rate was 87% in the CP group and 86% in the FM group (P = 0.952).
Conclusions
A new fat-dissociation method could reduce the time for searching lymph nodes without reducing number of lymph node. It is effective in high BMI patients and right-side CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
64P - Entrectinib in locally advanced/metastatic ROS1 and NTRK fusion-positive non-small cell lung cancer (NSCLC): Updated integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Filippo de Braud
Session: Poster display session
Resources:
Abstract
65P - Updated efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: Integrated analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster display session
Resources:
Abstract
66P - Brain metastases, treatment patterns and outcomes in ROS1-positive NSCLC patients from US oncology community centers
Presenter: Matthew Krebs
Session: Poster display session
Resources:
Abstract
67P - Pooled safety analysis of tepotinib in Asian patients with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
68P - A novel anti-EGFR antibody HLX07 for potential treatment of squamous cell carcinoma of the head and neck
Presenter: Ming Mo Hou
Session: Poster display session
Resources:
Abstract
69P - Irinotecan and cisplatin therapy-induced neutropenia as a prognostic factor in patients with extensive-disease small cell lung cancer
Presenter: Hiroshi Ishikawa
Session: Poster display session
Resources:
Abstract
70P - Is safe and efficient by intraoperative endoscopic nasobiliary drainage over primary closure of the common bile duct for cholecystolithiasis combined with common bile duct stones: A meta-analysis
Presenter: Jiasheng Cao
Session: Poster display session
Resources:
Abstract
71P - Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: A propensity score analysis
Presenter: Chaobin He
Session: Poster display session
Resources:
Abstract
72P - Novel technique of near-focus mode for accurate operation during endoscopic submucosal tunneling procedure: A two-center comparative study
Presenter: Wei Peng
Session: Poster display session
Resources:
Abstract
73P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumour mouse models
Presenter: Rachel Sparks
Session: Poster display session
Resources:
Abstract